NCT06780254View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Single- and Multiple-Ascending Doses of MH-001 in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

March 21, 2025

Study Completion Date

June 30, 2025

Conditions
Healthy
Interventions
DRUG

MH-001

capsules

DRUG

Placebo

capsules

Trial Locations (1)

G1P 0A2

RECRUITING

Syneos Health clinic, Québec

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

PrimeVigilance Ltd., UK

INDUSTRY

lead

Vespina Lifesciences Inc.

INDUSTRY